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Objective. The aim of this study was to evaluate clinicopathological ﬁndings and the eﬃcacy of the treatment modalities used
in patients with olfactory neuroblastomas. Study Design. Retrospective record review. Setting. Istanbul University, Cerrahpasa
Medical Faculty, medical oncology outpatient clinic. Subjects and Methods. There were 3 stage A tumors, 5 stage B and 11 stage
C according to the Kadish staging system. There were 5 grade I/II and 12 grade III/IV according to the Hyams’ histopathologic
system. Involvement to orbita was detected in eight patients at the time of diagnosis. Results. The median follow-up period was
23.7 months.The 5-year survival rate for the whole group was 26%. The stage A/B groups exhibited a better survival rate than the
C group with 2-year survival rates being 25 versus 71% respectively (P = .008). The grade I/II groups exhibited a better survival
rate than the grade III/IV groups with 2-year survival rates being 50 versus 16% respectively (P = .001). The group who had
orbitalinvolvement exhibited a poor survival rate than thegroup of patients who had noinvolvement of the orbital.Conclusion.I n
our study, tumorstage, histopathologicgrading,involvement ofthe orbita, brainand bone marow metastases were the statistically
signiﬁcantprognostic factors.
1.lntroduction
Olfactory neuroblastoma (ONB) is a rare malignant tumor
arising from the olfactory epithelium of the nasal cavity
and the paranasal sinuses. Berger et al. ﬁrst described this
uncommon neoplasm in 1924 [1]. This tumor commonly
invades paranasal sinuses and the adjacent structures. The
anatomic origin in the superior nasal cavity leads to
nonspeciﬁc symptoms that make early diagnosis diﬃcult.
Direct extension of the tumor into the anterior cranial fossa,
either at presentation or at disease recurrence, is common.
The most common symptoms at presentation were reported
as nasal stuﬃness and intermittent epistaxis. ONB is mostly
a locally aggressive tumor that can spread to lymph nodes
but metastatic involvement of bone, bone marrow, and
other organs was also reported. The most commonly used
staging system proposed by Kadish is currently based on
computer tomography and magnetic resonance imaging. In
stage A, the tumor is limited to the nasal cavity, in stage
B the tumor extends to paranasal sinus, and in stage C
the tumor is extending over the nasal cavity and sinus
and/or metastasized distantly [2]. A histological grading
system based on microscopic ﬁndings proposed by Hyams at
1988 showed a clear correlation of survival with histological
diﬀerentiation of disease [3].
Because of the rarity of olfactory neuroblastoma there
is no consensus on its management. However most authors
believe that craniofacial resection followed by RT oﬀers the
gold standard treatment in this disease. Despite aggressive
therapies, local, regional relapse, and distant metastasis
occur frequently and often after extended periods of follow-
up. Data for this case series were acquired retrospectively2 ISRN Oncology
from the ﬁles of Division of Medical Oncology, Cerrahpasa
Medical Faculty, Istanbul University. Additional information
regarding the clinical course and outcome was collected
from the patients’ charts and phone calls to the patients,
their relatives, and their general practitioners. In this study,
we have reviewed 19 cases of olfactory neuroblastomas
treatedover24-yearperiodandanalyzed theclinicalfeatures,
treatment outcomes, and prognostic factors.
2.PatientsandMethods
The data of nineteen patients of olfactory neuroblastomas
treated and followed up between 1986 and 2010 at Divi-
sion of Medical Oncology, Cerrahpasa Medical Faculty,
Istanbul University, were analyzed retrospectively. Patient
characteristics, initial symptoms, tumor extent, histologic
features, primary therapy, tumor recurrence, and treatments
of recurrent disease were determined. Diagnosis of ONB was
based on histopathologic features and radiologic localization
of the tumor. Patients were staged according to the Kadish
staging system. A single pathologist with expertise in head
and neck neoplasms reviewed the histological specimens. We
also classiﬁed our cases according to Hyams’ histopathologic
grading system. Local ethics committee’s approval and
patients’ or their next of kin’s informed consent were taken
before the study.
3.StatisticalAnalysis
Treatment response was assessed by clinical examinations
and computed tomography (CT) or magnetic resonance
imaging(MRI).Survivalrateswerecalculatedfromdiagnosis
to the death of the patient using the Kaplan-Meier life table
method. Curves were compared using the log-rank test. The
analyseswereperformed usingSPSS15.0(SPSSInc.Chicago,
IL, USA) software.
4.Results
4.1. Patient Characteristics. 19 patients (10 males/9 females)
were included in the analysis. The madian age at diagnosis
was 46 (range: 19 to 68 years). The peak incidence occurred
at the fourth decade (5/19, 38%). Tumor staging was Kadish
stage A in 3, stage B in 5, and stage C in 11 patients.
There were 5 grade I/II and 12 grade III/IV according
to the Hyams’ histopathologic grading system. There was
involvement to orbita in eight patients at the time of
diagnosis. Four patients had metastasis of cervical lymph
nodes, two brains, one bone marrow, one bone and lung
metastases, and one bone, mediastinal lymph node, and
liver metastases at the time of diagnosis. Tumor localization,
clinicalsymptoms, and presentations at thetime ofdiagnosis
are listed in Table 1. Median time from onset of ﬁrst
symptoms until diagnosis was 8.8 months (range: 1.8–29
months). The common presenting symptoms were nasal
obstruction (53%), epistaxis (31%), rhinorrhea, and facial
pain (26%). Patient characteristics, treatment modalities,
and outcome are summarized in Table 2.
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Figure1:Overallsurvivalinpatientswitholfactoryneuroblastoma.
4.2. Treatment. Patient treatments consisted of surgical
resection, radiation therapy, and chemotherapy (CTX)
(Table 3). Initial treatments included surgery alone in three
patients, radiotherapy (RT) with or without CTX in ﬁve,
surgery plus postoperative RT in seven and multimodality
therapy (surgery plus postoperative CTX plus postoperative
RT) in three, and ﬁnally CTX alone in one. In 14 patients,
craniofacial resection was the primary treatment modality.
Four of these patients had also radical neck dissection due to
cervical lymph nodes involvement. Nasal tumor resection in
2 patients, maxillectomy plus orbital exenteration in 1, and
external ethmoidectomy (EE) in 1 were also used as surgical
treatments. Of these 14 patients who underwent surgical
tumor resection, 4 were treated with surgery alone, 5 with
adjuvant radiation therapy after surgery, 2 with adjuvant
CTX after surgery, and the remaining 3 with radiation
therapy and CTX after surgery. Of the remaining 5 patients,
four in advanced stage and one in early stage refused surgical
treatment. Radiation therapy was administered to two of the
patients,radiation therapyfollowed byCTXtotheothertwo,
and CTX alone to one patient. The average radiation dose
was 57.9 Gy and the CTX was chosen from cisplatin-based
regimens. As a part of the primary treatment modality, 12
patientsunderwent radiationtherapy,so didtheﬁverelapsed
patients. As a part of primary treatment modality 8 patients
received CTX, so did the three relapsed patients.
4.3. Survival. The 5-year survival rate of all patients was
26%. The mean survival time was 23 months (Figure 1).
Fifteen patientsdiedoftumorprogression duringthefollow-
up, of whom 9 were at an advanced stage (Stage C) by
the time of diagnosis and 6 at an early stage (Stage A/B).ISRN Oncology 3
Table 1: Tumor localizationand symptoms at the time of diagnosis.
Patient no. Tumor localization Symptoms First symptoms until time
of diagnosis (months)
1 Sphenoid sinus-Nasal cavity Rhinorrhea 3.7
2 Nasal cavity Visual disturbance + Nasal obstruction +
Rhinorrhea + Neck mass 1.8
3 Nasal cavity + Ethmoid + Maxilar sinus Nasal obstruction 7
4 Nasalcavity Nasalobstruction + Tears 9
5 Maxilar sinus Nasal obstruction + Visual disturbance +
Rhinorrhea + Neck mass 3.6
6 Sphenoid sin¨ us + Nasalcavite Rhinorrhea 3.7
7 Ethmoid + Maxilar + Frontal + Orbita Visual disturbance + Nasal obstrucsion +
Rhinorrhea + Neck mass 1.8
8 Maxilar sinus + Orbita Nasal obstruction + Epistaxis + Facial
pain + Facial mass 25
9 Frontal sinus + Orbita Eyeball pain 3
10 Maxilar sinus + Orbita Teethache + Epistaxsis + Visual
disturbance 9.2
11 Frontal sinus + Orbita Exophthalmus 1.6
12 Nasal cavity Nasal obstruction + Epistaxis + Facial
pain + Facial mass 5.2
13 Ethmoid + Sphenoid sinus Facial pain + Neck mass 29
14 Retropharyngeal Facial paralysis + Earache 17.2
15 Nasal+ Sphenoid + Orbita Nasal obstruction + Exophthalmus +
Epistaxis 8.1
16 Sphenoid sinus + Orbita Headache + Proptosis 3
17 Sphenoid sinus + Orbita Headache + Earache + Facial pain 4
18 Nasal cavity Nasal obstruction + Epistaxis 24.5
19 Nasal cavity Nasal obstruction + Epistaxis + Facial
pain + Facial mass 6.5
Kadish stage C patients had a signiﬁcantly poorer outcome
compared to the stage A/B patients (2-year survival rate: 71
versus 25%, resp.; P = .008) (Figure 2). Histopathologically
high-grade patients (Grade 3/4) had a signiﬁcantly poorer
outcome when compared to the lower grade (Grade 1/2)
patients (2-year survival rate: 16 versus 50%, resp.; P =
.001) (Figure 3). Primary tumor extensions to orbital area
had a signiﬁcantly poorer outcome compared to the tumors
with no extension to orbital area (2-year survival rate: 22
versus 60%, resp.; P = .042) (Figure 4). There was no
statistically signiﬁcant diﬀerence in survival rate between
maleandfemalepatients(2-yearsurvivalrate:40versus44%,
resp.; P = .068). Patients with age <45 years had no poorer
outcome compared to patients with age >45 years (2-year
survival rate: 41 versus 43%; P = .059). Brain and bone
marrow involvements showed poorer outcome compared to
those without such involvement (Median survival rate: 9.1
versus 28.8 months, resp.; P = .001). Survival rate was
not signiﬁcantly diﬀerent among pateints of Kadish C when
stratiﬁed according to initial treatment (P = .8).
4.4. Locoregional Recurrence and Distant Metastases. Twelve
cases of recurrence occurred during follow-up periods
(63%). Locoregional recurrence developed in 6 and distant
metastasis in 6 patients. During the follow-up period, these
groups exhibited distant metastasis to the brain, spinal cord,
bone, bone marrow, meninges, and lungs. (Table 2). The
median recurrence-free survival was 8.4 months (range, 1–
124). As a treatment for recurrence and metastasis, reopera-
tion of primary site plus radiation therapy in 4 patients and
radiationtherapyalonein4 patientswere oﬀered.Combined
radiation therapy and CTX were performed in 6 patients.
The remaining 2 patients were treated with palliative care. Of
the 12 cases of recurrence and metastasis, 10 patients died.
Two patients were still alive at the time of preparation of this
manuscript.
5.Discussion
ONB is a rare malignant tumor that comprises 4,65% of
malignant nasal and paranasal tumors [4]. Some 1000 cases
have been reported in the English literature since it was
ﬁrst introduced in 1924 [5]. The incidence rate is bimodal,
with peaks in the second and third decades of life and
in the sixth and seventh decades of life and equal among
females and males. As for our study, the age at diagnosis
was most common in the fourth decade and female-to-male
ratio was equal. The average time between the appearance4 ISRN Oncology
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Table 3: Treatment modalities.
Patient no. Surgical procedure CTX Duration of CTX
(Months)
Total radiotherapy fraction
(Gy)
1 Craniofacial resection 50
2— cisplatin + etoposid 8 56
3 Craniofacial resection 65
4—
cisplatin + etoposid
ndoxan + vincristin +
doxorubicin
12 65
5— 60
6 Craniofacial resection 50
7— 60
8 Maxillectomi + Orbital exenteration 50
9 Craniofacial resection 36
10 — 66
11 Craniofacia resection cisplatin + etoposid 5 60
12 Craniofacialresection cisplatin + etoposid 5 56
13 External thmoidectomy cisplatin + etoposid
cisplatin + vinkristin 10 60
14 — cisplatin + etoposid
carboplatin + etoposid 7
15 Craniofacialresection
16 Craniofacialresection
17 Craniofacialresection Cisplatin 1 70
18 Nasal resection
19 Nasal resection 54
(month)
200 150 100 50 0
C
u
m
s
u
r
v
i
v
a
l
1
0.8
0.6
0.4
0.2
0
A/B-censored
C
A/B
Figure2:Survivalinpatientswitholfactoryneuroblastomaaccord-
ing to Kadish stage.
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Figure 3:Survivalinpatientswitholfactoryneuroblastomaaccord-
ing to Hyams’ histopathologicalclassiﬁcation.6 ISRN Oncology
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Figure4:Survivalinpatientswitholfactoryneuroblastomaaccord-
ing to orbital involvement.
of the ﬁrst symptom and the diagnosis was reported as
6 months and this period was similar also in our group
[6]. The most common symptoms at the initial diagnosis
were deﬁned as unilateral nasal obstruction and epistaxis
in the literature. Our patients had similar symptoms at the
initialdiagnosis. Therearenouniversallyaccepteddiagnostic
criteria for making the diagnosis of ONB. The characteristic
histopathological morphology is a small blue cell neoplasm
withalobulararchitecture. Thistumormaybemisdiagnosed
as an undiﬀerentiated small cell carcinoma, melanoma,
rhabdomyosarcoma, or other small blue cell neoplasms.
Hyam proposed a grading system with grades 1–4 based on
t h ep r e s e n c eo ra b s e n c eo fs e v e nd i ﬀerent histopathological
parameters. These are growth, architecture, mitotic activity,
necrosis, nuclear pleomorphism, rosette formation, and
ﬁbrillary stroma [3].
Immunohistochemistry is a valuable diagnostic tool.
Staining paterns for neuron-spesiﬁc enolase, chromogranin,
synaptophysin, S-100, and epithelial markers can be helpful
[7].
There is evidence that histological grade of ONB inﬂu-
ences biologic behavior, particularly because it relates to
disease progression, local recurrence, and metastasis. For the
well-diﬀerentiated tumors a slower disease progression and
lesstendencyforlocalrecurrencehavebeendescribed.Inour
study, the 2-year survival rate of this grade I/II-III/IV disease
was 16 versus 50%, respectively. These observations suggest
that the histopathological grading can have a prognostic
value. More aggressive treatment, such as surgery, radiation,
and intensive CTX, may be useful for patients with grade
III/IV disease. A meta-analysis showed that the median
overall survival at 5 years is 45% in 390 patients [8]. The
distribution of ONB from 21 studies according to Kadish
staging system was 12% at stage A, 27% at stage B, and 61%
at stage C. The mean 5-year survival is 75% for stage A, 68%
for stage B, and 41% for stage C [9]. The conclusions of the
University of Virginia stated that Kadish stage is predictive of
disease-related mortality [10]. However, in the series of the
Mayo Clinic it was found that Kadish stage did not aﬀect
the outcome [11]. Danish clinicopathological study found
that the staging system of Kadish was able to stratify into
prognostically signiﬁcant groups [11]. In our study, the 5-
year survival rate of these tumors was 26% and median
survival time was 23 months. The distribution of ONB
according to Kadish staging system was 16% at stage A, 26%
stage B, and 58% stage C. However, in our study, the 5-year
survival rates ofthese stagegroupswere inferior comparedto
those reported in other studies. The cause of this poor result
was presentation of 5 patients with distant metastases (26%;
2 brain, 1 bone marrow, 2 other sites), 4 patients (21%)
with cervical lymph node metastasis, 12 patients (63%) with
high-grade histology at the time of diagnosis, and inability
to evaluate the surgical margins of the resected tumors. ONB
can be disseminated both locally and distantly. The most
common site of metastasis in published series is cervical
lymph nodes. The survival rate of node positive patients is
29% compared with 64% of node negative patients [12].
Distant metastases have been described in the pancreas,
the liver, mediastinum, bone marrow, lungs, leptomeninges,
skin, and breasts [11, 12]. Cervical nodal metastases can
develop in 17 to 33% of patients and distant metastases in
10 to 40% of patients over the course of disease [12, 13].
Craniofacial resection followed by RT seems to decrease
recurrence to 10% [12]. Metastatic disease at presentation
occurs in 10 to 50% of patients, depending on the study
[6, 13, 14] .T h em o s tc o m m o ns i t eo fm e t a s t a t i cs p r e a d
is the cervical lymph nodes. Approximately 20 to 30% of
metastatic disease involves the central nervous system [6].
Salvage therapy after local recurrence is possible in 30–35%
of cases. In our group, there were 12 (63%) patients who
relapsed after initial surgery. We found the local recurrence
rate to be 31.5% and distant metastasis 31.5% after initial
surgery. Duringthefollow-upperiodsthesegroupsexhibited
distant metastases to the brain, spinal cord, bone, bone
marrow, meninges, and lungs. Patients who had brain and
bone marrow metastases had poorer prognosis than others
having metastatic deposits of other sites. Involvement of the
orbit is a serious prognostic factor, but when the orbital
periosteum is aﬀected without penetration into the orbital
structures themselves, the eye may be preserved by resection
and grafting of the periosteum without an adverse eﬀect
on survival as compared with orbital clearance. Irrespective
to the most sophisticated imaging, involvement of the dura
and orbital periosteum can accurately be determined only at
surgery. In our study, involvement of the orbita is considered
as a poor prognostic factor. This group’s (8 patients) survival
rate is poorer than those with no involvement of the orbita
(P = .042). The Institute of Laryngology and Otology, Uni-
versity College London, published a study of 42 patients
treated over 23 years. Craniofacial resection was used inISRN Oncology 7
all cases. Fifty-seven percent of patients received surgery
combined with radiation therapy. Overall and disease-free
survival rates were 77 and 61% at 5 years, and 53 and 42%
at 10 years, respectively. Intracranial extension and orbital
involvement were associated with worse outcome. Late
recurrences were seen. Based on this experience, combined
therapy with craniofacial resection and radiation therapy is
recommended by this group [15]. In a retrospective study
of 47 patients treated at multiple centers in Germany from
1979 to 2001, most of the patients were presented with stage
C disease. The 5-year overall survival and event-free survival
rate were 64% and 50%, respectively. Patients who received
multimodality therapy had a signiﬁcantly better event-free
survival rate compared with those who did not receive
multimodality therapy (74 versus 41%). The authors recom-
mend a combination therapy including CTX, surgery, and
postoperative radiation therapy for Kadish stage C patients
[16]. In our study, initial treatment included surgery alone
in three patients, RT with or without CTX in ﬁve, surgery
plus postoperative RT in seven, and multimodality therapy
(Surgery plus postoperative CTX plus postoperative RT) in
three, only CTX in one patient. However, in our study choice
of treatment modality did not show a statistically signiﬁcant
diﬀerence in survival rate. The reasons for that might be
includinglownumberofpatientsinthestudy,being5distant
site metastasis, 4 cervical lymph node metastasis at the time
of diagnosis, only one orbital exentration (although there
were 8 orbital involvement), and 12 patients exhibiting high
grade histology and inability to evaluate surgical margins in
resected tumors.
In conclusion, advanced tumor stage, the initial histo-
pathologic grade of III/IV, and involvement of orbita, brain,
or bone marrow metastasis were the statistically signiﬁcant
poor prognostic factors, whereas age, sex, and treatment
modality were not prognostic factors. Orbital exentration
should be recommended to patients who have orbital in-
volvement. Kadish C was a heterogeneous group. Only
cervical metastasis was a better prognostic factor among
other distant metastases.
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